Goldman Sachs Puts Jazz Pharmaceuticals on Buy List with $337 Price Target
Jazz Pharmaceuticals has received a boost from Goldman Sachs, which initiated coverage on the company with a buy rating and a price target of $337.00.
The stock has delivered an 81% return over the past year and currently trades at $234.88, with a market capitalization of $15.25 billion.
Jazz Pharmaceuticals is a global biopharmaceutical company with a commercial and research pipeline of assets in neuroscience and oncology.
The revenue base is driven by continued utilization of Xywav, a low sodium oxybate treatment for narcolepsy and idiopathic hypersomnia, and Epidiolex, a therapy for rare epilepsy.
Goldman Sachs analyst Andrea Newkirk said the launches for Ziihera, known as zanidatamab, in HER2-expressing biliary tract cancer and gastroesophageal adenocarcinoma represent the next legs of growth.